For the quarter ending 2025-09-30, NBY had -$3,119K decrease in cash & cash equivalents over the period. -$1,840K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -1,293 | 5,748 |
| Net income from discontinued operations, net of taxes | -40 | -11,042 |
| Depreciation of property and equipment | 2 | 3 |
| Stock-based compensation expense related to employee and director stock awards | 0 | 6 |
| Non-cash expense incurred to obtain consent of secured convertible note holders | 0 | 0 |
| Non-cash gain on changes in fair value of warrant liability | 0 | 0 |
| Non-cash loss on changes in fair value of embedded derivative liability | 0 | 0 |
| Non-cash loss on modification of warrants | 0 | 0 |
| Non-cash right-of-use asset amortization | 33 | 90 |
| Impairment of long-lived assets | 87 | 589 |
| Inventory | - | 467 |
| Accretion of interest and amortization of debt discounts on convertible notes | 38 | 46 |
| Accounts receivable | 368 | 0 |
| Prepaid expenses and other current assets | -83 | 32 |
| Other assets | -2 | -1 |
| Accounts payable and accrued liabilities | -741 | 919 |
| Operating lease liabilities | -110 | -176 |
| Net cash used in operating activities, continuing operations | -1,840 | -4,315 |
| Purchases of property and equipment | 0 | 0 |
| Net cash used in investing activities, continuing operations | 0 | 0 |
| Net proceeds from issuance of series d preferred stock-Series DPreferred Stock | 3,786 | - |
| Cash payment pursuant to series f agreements-Series FPreferred Stock | 527 | - |
| Proceeds from warrant exercises-Warrants And Prefunded Warrants | 237 | 614 |
| Proceeds from issuance of common stock and pre-funded warrants in an underwritten registered direct offering, net of issuance costs-Underwritten Registered Direct Offering | 0 | - |
| Payments on secured convertible notes | 0 | 0 |
| Repurchase of series f-1 and f-3 warrants | 0 | 1,989 |
| Payment on bridge note | 0 | 507 |
| Dividend paid | 4,815 | - |
| Cash debt issuance cost | 0 | 0 |
| Net cash (used in) provided by financing activities, continuing operations | -1,319 | -1,882 |
| Net decrease in cash, cash equivalents, and restricted cash, continuing operations | -3,159 | -6,197 |
| Net increase in cash and cash equivalents, discontinued operations | 40 | 11,111 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash, consolidated | -3,119 | 4,914 |
| Cash and cash equivalents at beginning of period | 907 | - |
| Cash and cash equivalents at end of period | 2,702 | - |
NovaBay Pharmaceuticals, Inc. (NBY)
NovaBay Pharmaceuticals, Inc. (NBY)